세계 접촉성 피부염 치료 시장 – 2023-2030

Overview
Global contact dermatitis treatment market reached US$ xx billion in 2022 and is expected to reach US$ xx billion by 2030, growing with a CAGR of xx% during the forecast period 2023-2030.
The global contact dermatitis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The itchy rash disease referred to as contact dermatitis may be brought on by an allergic reaction to a substance or by coming into direct contact with it. Even if the rash is contagious, it can still be very unpleasant. Numerous things, such as perfumes, jewelry, plants, and cosmetics, might cause this reaction. The rash often emerges days after exposure.
Exposure to a chemical that affects the skin or sets off an allergic reaction is what leads to contact dermatitis. The material might be one of hundreds of thousands that are recognized irritants and allergies. People frequently have simultaneous allergic and irritant reactions.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products for novel treatments such as barrier creams or medications for allergic contact dermatitis and boost the global contact dermatitis treatment market.
Market Dynamics: Drivers & Restraints
Increasing demand for novel treatment options
Finding and eliminating any suspected causative factors is the only effective treatment for irritant contact dermatitis (ICD). While a number of symptomatic therapies can temporarily relieve pruritus, topical corticosteroids remain the basis of treatment. The patient is at a greater risk for developing chronic or recurring dermatitis if any probable causal agents are not found and removed, which is the only effective treatment for allergic contact dermatitis.
For instance, recently a combination of antioxidants, moisturizers, and strong free radical scavengers or inhibitors were created by the study team to prevent an inflammatory reaction to the irritant. In the affected area, the lotion lowered swelling, soothed itching, and preserved peripheral nerves. Contrarily, the experimental cream effectively cured allergic contact dermatitis without any of the negative side effects associated with corticosteroids in mice. The LSU Health New Orleans Neuroscience Center of Excellence and the National Institute of General Medical Sciences both provided funding for the study.
Additionally, on August 30, 2023, according to the agreements disclosed on April 3, 2023, L'Oréal accomplished its purchase of distinctive premium beauty brand Aesop. The Aesop brand taps into all of today's escalating currents with its distinctive fusion of urbanity, hedonism, and unquestionable elegance.
Furthermore, the rising utilization of novel medicines and solutions for contract dermatitis. Rising irritant contact dermatitis cases and increasing utilization of several drugs along with research for innovative product development will be a major factor driving the growth of the contact dermatitis treatment market.
Side effects associated with the cleansers or creams
Although it may be rare, some drug users may encounter very serious, even fatal, negative effects. A rash, hives, itching, red, blistered, swollen, or peeling skin both with and without fever, wheezing, chest tightness, difficulty breathing, swallowing, or speaking, unusual hoarseness, or edema of the mouth, lips, face, tongue, or throat are all indications of an allergic response.
Skin infection symptoms include leaking, heat, redness, swelling, or soreness and abnormal bleeding from the affected area. When used on the face, several occlusive barrier creams might exacerbate acne. The majority of barrier creams shouldn't be put on injured skin directly.
Segment Analysis
The global contact dermatitis treatment market is segmented based on disease type, treatment, route of administration, end user and region.
Irritant contact dermatitis disease type segment accounted for approximately 80% of market share
Acute or persistent skin inflammation brought on by cutaneous contact with a biologic, chemical, or physical factor is known as contact dermatitis. Clinically, it may be challenging to distinguish between irritating and allergic contact dermatitis following only one or several exposures. Direct tissue injury following a single encounter or several exposures to a recognized irritant results in irritant contact dermatitis (ICD).
The duration, potency, and amount of the drug all affect how likely it is that irritating contact dermatitis may manifest. Irritant contact dermatitis can be brought on by skin irritation brought on by chemical, physical, or microtrauma factors. Irritating contact dermatitis is more common in women, children, older people, and people with atopic tendencies. According to reports, irritating contact dermatitis accounts for up to 80% of instances of occupational dermatitis.
The quantity and intensity of the irritant, the duration, and the frequency of exposure are the elements that affect how severe irritant contact dermatitis is. It also relies on the skin's characteristics, such as whether it is thick, thin, greasy, dry, extremely light, previously injured, or has an atopic propensity. The severity is also influenced by environmental factors including extremes in temperature and humidity.
On March 8, 2022, the US Food & Drug Administration (USFDA) gave its final approval to Alembic Pharmaceuticals Limited's collaboration with Aleor Dermaceuticals Limited's Abbreviated New Drug Application for Triamcinolone Acetonide and Nystatin Ointment USP, 100,000 units/gram. Nystatin with Triamcinolone Acetonide Ointment is recommended for the management of cutaneous candidiasis; studies have shown that during the initial few days of treatment, the nystatin-steroid combination is more beneficial than the nystatin component alone.
Geographical Penetration
North America accounted for around 39% of market share in 2022
Due to the rising need for contact dermatitis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for contact dermatitis treatment.
Increasing expenditure on healthcare, advancement of technologies and different treatment products for different dermatitis diseases, along with increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of contact dermatitis treatment market share of this region. The market in this area is growing as people become more aware of various novel treatments. The aforementioned elements attest to North America's hegemonic position in the world.
North America continues to be a key player in the global contact dermatitis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for contact dermatitis medications in the United States have been proactive in executing several initiatives or treatments, stimulating these medications demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global contact dermatitis treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of barrier creams or cleansers, was significantly impacted. The widespread lockdowns and restrictions imposed by the pandemic, which began in early 2020, had an effect on a number of initiatives all around the world.
Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for contact dermatitis treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global contact dermatitis treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel treatments.
By Disease Type
• Irritant Contact Dermatitis
• Allergic Contact Dermatitis
By Treatment
• Barrier Creams
o Ceramide Containing Creams
o Dimethicone Containing Creams
• Cleansers
• Medications
o Immunomodulators
o Corticosteroids
o Antihistamines
o Tricyclic Antidepressants
o Chelation Agents
o Immunosuppressive Agents
o Calcineurin Inhibitors
• Phototherapy
• Others
By Route
• Oral
• Topical
• Others
By End User
• Hospitals
• Specialty Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On September 21, 2023, According to revenue, Kenvue Inc., the most prominent pure-play health care company globally, presented their research on oatmeal cream as a successful method for treating atopic dermatitis among Black children. Additionally, Kenvue highlighted other industry-advancing information at the information of Skincare Summit in addition to sharing Neutrogena's newest cleansing and hydration products.
• On January 17, 2023, preliminary topline outcomes from a Phase 2b research trial evaluating different concentrations of the Edesa's drug candidate, EB01, as a standalone therapy for moderate to serious chronic Allergic Contact Dermatitis (ACD) were released by Edesa Biotech, Inc., a biopharmaceutical company in the clinical stage focused on inflammatory as well as immune-related illnesses. Lowest effective dose was effectively established by the study, and the 1.0% formulation achieved the primary endpoint exhibiting statistical significance.
• On September 21, 2021, with the introduction of new and better formulas that further develop the science behind the venerable brand, sensitive skincare company Cetaphil reinforces its dedication to clinically-proven sensitive skincare. A dermatologist-endorsed combination of Panthenol (Vitamin B5), Niacinamide (Vitamin B3), and moisturizing Glycerin has been added to the brand's most well-known products to increase skin's general resistance.
Competitive Landscape
The major global players in the market include Bausch Health Companies Inc., GALDERMA, L’Oréal, Kenvue, Edesa Biotech, Inc., Astellas Pharma Inc., Hapten Sciences, Glenmark Pharmaceuticals U.S. Inc., Teva Pharmaceutical Industries Ltd. and Bristol-Myers Squibb Company among others.
Why Purchase the Report?
• To visualize the global contact dermatitis treatment market segmentation based on disease type, treatment, route of administration, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of contact dermatitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global contact dermatitis treatment market report would provide approximately 69 tables, 67 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies